United Kingdom· GB-APID-42579211000001105
Elrexfio 44mg/1.1ml solution for injection vials
A elranatamab product containing elranatamab, registered in United Kingdom by Pfizer Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Elranatamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX32 (elranatamab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Elranatamab · ATC L01FX32
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Elranatamab
- Manufacturer
- Pfizer Ltd
- Country
- United Kingdom (GB)
- ATC code
- L01FX32
- ATC class
- Elranatamab
- Defined daily dose
- 5.43 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5415062395998
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elranatamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesElrexfioPfizer Laboratories Div Pfizer Inc
- CanadaELREXFIOPFIZER CANADA ULC
- SwitzerlandElrexfio
- CzechiaELREXFIOPfizer Europe MA EEIG, Bruxelles
- BelgiumElrexfio 40 mg/mlPfizer Europe MA
- Japanエルラナタマブ（遺伝子組換え）ファイザー
- FranceELREXFIO 40 mg/mL, solution injectablePFIZER EUROPE MA EEIG (BELGIQUE)
- IrelandELREXFIO 40 mg/mL solution for injectionPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Elrexfio
- Liechtenstein · Elrexfio
- Norway · Elrexfio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef1e2564-9005-4c47-98ef-41dca7a16e75 GET /v1/drugs/ef1e2564-9005-4c47-98ef-41dca7a16e75?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42579211000001105",
"desc": "Elrexfio 44mg/1.1ml solution for injection vials (Pfizer Ltd)",
"form": "Solution for injection",
"vpid": "42655411000001101",
"source": "dmd",
"vtm_id": "42598211000001107",
"strength": "40 mg",
"substance": "Elranatamab",
"ingredient": "Elranatamab",
"supplier_code": "2082201000001106"
}See everything about elranatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.